Celaid Therapeutics adds Shionogi, Teikoku to Series B

Celaid Therapeutics has completed the second close of its Series B financing, bringing in Shionogi & Co. and a corporate venture firm linked to Teikoku. The company has not disclosed the amount raised, though reports suggest around $2.6 million (JPY 400 million) for this portion of the round.

The capital arrives as Celaid moves toward later-stage development of its pipeline. Its lead program, CLD-001, is among the assets expected to progress in the near term. The company’s focus on underserved conditions may have drawn interest from backers with experience in specialty markets.

Shionogi’s participation follows its recent activity in the sector, while the other investor’s involvement could reflect broader industry trends—corporate venture groups often seek exposure to early-stage technologies with potential applications beyond their core businesses.

What happens next will shape perceptions of the round. If CLD-001 advances into further testing, it may offer clearer signals about the company’s trajectory. For now, the funding serves as another example of cross-border collaboration in a sector where partnerships often outpace standalone growth.

Sources: msn.com